Novo Nordisk的血浆试验显示,平均体重下降20.7%,有希望治疗肥胖症。 Novo Nordisk's semaglutide trial shows significant 20.7% average weight loss, promising for obesity treatment.

Novo Nordisk报告说,其第3b阶段STEP UP试验显示,7.2毫克的硫酸盐在72周后导致明显平均体重下降20.7%,而安慰剂为2.4%。 Novo Nordisk reports that its phase 3b STEP UP trial showed semaglutide 7.2 mg led to a significant average weight loss of 20.7% after 72 weeks, compared to 2.4% for a placebo. 药物开销良好,副作用主要是胃肠胃。 The medication was well-tolerated, with side effects primarily gastrointestinal. 结果表明, 赛马格卢提德在治疗肥胖症方面具有潜力, 补充其对心血管健康的益处. Results indicate potential for semaglutide in treating obesity, complementing its benefits in cardiovascular health.